Suzanne Lentzsch, MD, PhD
Dr. Lentzsch is an Associate Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.
Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia.
Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.
Dr Lentzsch' translational laboratory research work provided critical insights to understanding of the mechanism of action of thalidomide and IMiDs in multiple myeloma and bone disease. With the goal to bring findings from bench to beside, her current RO1 funded laboratory research investigates the role of metallo-proteinases in multiple myeloma bone disease in order to develop new strategies to target myeloma bone disease.
Dr Lentzsch is leading many phase 1, 2 and 3 clinical trials, including investigator-initiated studies for amyloidosis, newly diagnosed and relapsed/refractory multiple myeloma and for maintenance following transplant for multiple myeloma. She currently focuses on the evaluation of the monoclonal antibody 11-1F4 targeting amyloid directly and thereby inducing the break –up of amyloid. Further Dr. Lentzsch served as national principal investigator in Germany evaluating the role of lenalidomide in the treatment of relapsed Multiple Myeloma and is leading an international multicenter trial to evaluate the role of Xofigo in relapsed refractory multiple myeloma. As Co-Chair of the Pathways Committee, she played a major role in the development of the Multiple Myeloma Pathways at University Pittsburgh Medical Center.
Her research is funded by various grants and awards from e.g. the NIH, Pennsylvania Department of Health, the German Cancer Foundation, the Leukemia and Lymphoma Society , the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr Lentzsch has published over 70 original articles, editorials, chapters, many as the lead or senior author, in such prestigious journals as Journal of Clinical Investigations, Blood, Cancer Research, and Leukemia.